Ultragenyx director granted RSUs and stock options

Ultragenyx Pharmaceutical Inc. director Matthew K. Fust reported receiving equity compensation in the form of both restricted stock units and stock options.

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical Inc. director Matthew K. Fust reported receiving equity compensation in the form of both restricted stock units and stock options. He was granted 7,751 shares of Common Stock as Restricted Stock Units under the company’s 2023 Incentive Plan, bringing his direct common stock holdings to 33,696 shares following the award.

He was also granted a stock option for 14,058 shares of Common Stock with an exercise price of $25.80 per share, representing his full reported option position after this grant. Both the RSUs and the stock option vest in full on the earlier of the company’s next Annual Meeting of Stockholders or May 14, 2027.

Insider Trade Summary

Grant/Award: 21,809 shares

Grant/Award 2 txns

Insider Fust Matthew K

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	14,058	$0.00	$0.00
Grant/Award	Common Stock	7,751	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 14,058 contracts (Direct); Common Stock — 33,696 shares (Direct)

Footnotes (2)

1. F1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
2. F2. The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

Key Figures

RSU grant: 7,751 shares Common shares held: 33,696 shares Stock option size: 14,058 shares +3 more

6 metrics

RSU grant 7,751 shares Restricted Stock Units under 2023 Incentive Plan

Common shares held 33,696 shares Direct Common Stock ownership after RSU grant

Stock option size 14,058 shares Option covering Common Stock granted on May 14, 2026

Option exercise price $25.80 per share Exercise price for new stock option grant

Option expiration May 14, 2036 Expiration date of stock option

Vesting deadline May 14, 2027 Latest vesting date for RSUs and option, or earlier Annual Meeting

Key Terms

Restricted Stock Units ("RSUs"), 2023 Incentive Plan, Stock Option (Right to Buy), Annual Meeting of Stockholders

4 terms

Restricted Stock Units ("RSUs") financial

"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2023 Incentive Plan financial

"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) ... underlying security title "Common Stock""

Annual Meeting of Stockholders regulatory

"vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ultragenyx (RARE) director Matthew K. Fust report?

Director Matthew K. Fust reported receiving equity compensation, including Restricted Stock Units and stock options. The filing shows a grant of 7,751 RSUs and a stock option for 14,058 shares, both vesting based on the company’s next Annual Meeting or a set future date.

How many Ultragenyx (RARE) shares does Matthew K. Fust hold after this Form 4?

After the RSU award, Matthew K. Fust directly holds 33,696 shares of Ultragenyx Common Stock. This figure comes from the Form 4’s post-transaction ownership column and reflects his updated position excluding any separate derivative holdings like options.

What equity awards did Matthew K. Fust receive from Ultragenyx (RARE)?

He received 7,751 Restricted Stock Units and a stock option covering 14,058 shares of Common Stock. These awards were granted under Ultragenyx’s 2023 Incentive Plan as compensation, rather than representing any open-market purchases or sales of existing shares.

What is the exercise price and term of Matthew K. Fust’s new Ultragenyx stock option?

The new stock option has an exercise price of $25.80 per share and covers 14,058 shares. According to the filing, the option expires on May 14, 2036, giving a long-dated right to buy Ultragenyx Common Stock if vesting conditions are met.

When do Matthew K. Fust’s Ultragenyx RSUs and options vest?

Both the RSUs and the stock option vest in full on the earlier of Ultragenyx’s next Annual Meeting of Stockholders or May 14, 2027. This single vesting condition applies to the entire 7,751 RSUs and all 14,058 option shares disclosed in the footnotes.

Were Matthew K. Fust’s Ultragenyx (RARE) Form 4 transactions open-market buys or sales?

No, the transactions were equity grants, not market trades. The Form 4 uses transaction code “A” for both the RSU and option awards, indicating a grant or award acquisition rather than open-market buying or selling of Ultragenyx shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 06:50 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fust Matthew K

(Last) (First) (Middle)

C/O ULTRAGENYX PHARMACEUTICAL INC.

60 LEVERONI COURT

(Street)

NOVATO CALIFORNIA 94949

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		A		7,751(1)	A	$0	33,696	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$25.8	05/14/2026		A		14,058		(2)	05/14/2036	Common Stock	14,058	$0	14,058	D

Explanation of Responses:

1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

2. The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

	/s/ Karah Parschauer, attorney-in-fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)